JP2024544075A5 - - Google Patents

Info

Publication number
JP2024544075A5
JP2024544075A5 JP2024532467A JP2024532467A JP2024544075A5 JP 2024544075 A5 JP2024544075 A5 JP 2024544075A5 JP 2024532467 A JP2024532467 A JP 2024532467A JP 2024532467 A JP2024532467 A JP 2024532467A JP 2024544075 A5 JP2024544075 A5 JP 2024544075A5
Authority
JP
Japan
Prior art keywords
clofazimine
composition according
pharmaceutical composition
topical pharmaceutical
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544075A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080537 external-priority patent/WO2023102363A1/en
Publication of JP2024544075A publication Critical patent/JP2024544075A/ja
Publication of JP2024544075A5 publication Critical patent/JP2024544075A5/ja
Pending legal-status Critical Current

Links

JP2024532467A 2021-11-30 2022-11-29 ブルーリ潰瘍におけるマイコバクテリウム・ウルセランスの局所治療のための製剤及び方法 Pending JP2024544075A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284426P 2021-11-30 2021-11-30
US63/284,426 2021-11-30
PCT/US2022/080537 WO2023102363A1 (en) 2021-11-30 2022-11-29 Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers

Publications (2)

Publication Number Publication Date
JP2024544075A JP2024544075A (ja) 2024-11-27
JP2024544075A5 true JP2024544075A5 (cg-RX-API-DMAC10.html) 2025-12-05

Family

ID=86613091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532467A Pending JP2024544075A (ja) 2021-11-30 2022-11-29 ブルーリ潰瘍におけるマイコバクテリウム・ウルセランスの局所治療のための製剤及び方法

Country Status (5)

Country Link
US (1) US20240390366A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024544075A (cg-RX-API-DMAC10.html)
CN (1) CN118317771A (cg-RX-API-DMAC10.html)
AU (1) AU2022399569A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023102363A1 (cg-RX-API-DMAC10.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610198A (en) * 1994-03-18 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
WO2007085057A1 (en) * 2006-01-25 2007-08-02 The Council Of The Queensland Institute Of Medical Research A medical protocol
GB0709513D0 (en) * 2007-05-17 2007-06-27 Helperby Therapeutics Ltd Topical formulations
US9018216B2 (en) * 2012-07-18 2015-04-28 Vertex Pharmaceuticals Incorporated Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
WO2016179231A1 (en) * 2015-05-04 2016-11-10 Board Of Trustees Of Michigan State University Compositions and methods for inhibiting bacterial growth
US11572588B2 (en) * 2017-07-19 2023-02-07 The Regents Of The University Of Colorado, A Body Corporate Methods of evaluating treatment efficacy and/or treatment duration in mycobacterial diseases
WO2021184339A1 (en) * 2020-03-20 2021-09-23 Merck Sharp & Dohme Corp. Oxazolidinone compound and methods of use thereof as an antibacterial agent
CA3180160A1 (en) * 2020-04-17 2021-10-21 Shenzhen Pharmacin Co., Ltd Pharmaceutical compositions
JP7893751B2 (ja) * 2020-05-01 2026-07-22 マンカインド コーポレイション ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法

Similar Documents

Publication Publication Date Title
CA2779630C (en) Combination of azelastine and steroids
JP3522220B2 (ja) 細胞媒介性免疫病の処置
US20040138179A1 (en) Antifungal formulations
AU724070B2 (en) Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms
BR112012007087A2 (pt) composições farmacêuticas compreendendo compostos triptano e uso das mesmas para a preparação de um medicamento para tratar condições associadas à dor cefálica
EP0800388A1 (en) Compounds for veterinary and medicinal applications
WO2007123867A2 (en) Stable solutions of prostaglandin and uses of same
US20260083702A1 (en) Inhalation formulation for treating ipf disease and preparation method therefor
KR970008156B1 (ko) 소아의 비정형 폐렴의 치료 및 예방에 유용한 펜타미딘 염
US6007834A (en) Nasal melatonin composition
EP0859598A1 (en) Liposomes containing a corticosteroid
JP2024544075A (ja) ブルーリ潰瘍におけるマイコバクテリウム・ウルセランスの局所治療のための製剤及び方法
HK40111713A (en) Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers
WO1999051219A1 (en) Pleuromutilin derivatives for treating nasopharynx infection
AU695054B2 (en) Compounds for veterinary and medicinal applications
JP2000191537A (ja) 炎症性呼吸器疾患治療剤
WO2005053672A1 (ja) シロミラストまたはその塩を有効成分とする掻痒治療剤
JP2000186042A (ja) ラクトン誘導体を用いる炎症性呼吸器疾患治療剤
JP2001288082A (ja) 乾癬治療・予防用外用剤